YH010 is a fully human PD-L1 x IL-12 antibody-cytokine fusion protein developed for the treatment of solid tumors. This innovative therapy activates the IL-12 signaling pathway while simultaneously inhibiting PD-L1 binding to PD-1. Furthermore, YH010 has the potential to enhance the specific killing activity of T cells by tethering IL-12R positive T cells with PD-L1 positive tumor cells, providing an additional mechanism to attack cancer cells.
1. In vivo experiments have demonstrated that the safety of YH010 is dependent on the targeting affinity of the anti-PD-L1 antibody. Low binding capacity of the PD-L1 antibody may result in weight loss and elevated serum ALT, leading to serious side effects.
Figure 2. In the humanized PD-L1 syngeneic MC38 colorectal cancer model, YH010 demonstrated a stronger anti-tumor response than anti-PD-L1 antibodies.
PD-L1 immunosuppressants function to block the inhibitory binding of PD-L1 on tumor cells to PD-1 on T cells, which triggers programmed T cell death, leading to immune escape of tumor cells. By blocking this interaction, PD-L1 immunosuppressants can enhance T cell activity, enabling continuous recognition and elimination of tumor cells.